Principal Financial Group
ARIA

Principal Financial Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Principal Financial Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-142,761
Closed -$1.78M – 2276
2016
Q4 		$1.78M Buy
142,761
+111,344
+354% +$1.34M ﹤0.01% 1729
2016
Q3 		$430K Buy
31,417
+330
+1% +$3.31K ﹤0.01% 1885
2016
Q2 		$230K Buy
31,087
+1,468
+5% +$11K ﹤0.01% 1992
2016
Q1 		$189K Buy
29,619
+604
+2% +$3.38K ﹤0.01% 2022
2015
Q4 		$181K Buy
29,015
+689
+2% +$4.52K ﹤0.01% 2060
2015
Q3 		$165K Sell
28,326
-538
-2% -$4.14K ﹤0.01% 2054
2015
Q2 		$239K Buy
28,864
+2,281
+9% +$20.2K ﹤0.01% 2004
2015
Q1 		$219K Sell
26,583
-30
-0.1% -$222 ﹤0.01% 2005
2014
Q4 		$183K Sell
26,613
-7,650
-22% -$47.8K ﹤0.01% 2050
2014
Q3 		$185K Hold
34,263
– – ﹤0.01% 2048
2014
Q2 		$218K Buy
+34,263
New +$236K ﹤0.01% 2059
2013
Q4 		– Sell
-241,230
Closed -$4.44M – 2336
2013
Q3 		$4.44M Hold
241,230
– – 0.01% 1342
2013
Q2 		$4.22M Buy
+241,230
New +$4.28M 0.01% 1311

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Principal Financial Group's ARIA Position: Q1 2017 in Review

Principal Financial Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 142,761 shares — an estimated $1.78M sold.

Principal Financial Group first reported a position in ARIA in Q2 2013 and held it in 13 quarters. The position peaked at $4.44M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Principal Financial Group reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Principal Financial Group sold 142,761 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $1.78M.
  • Principal Financial Group first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Principal Financial Group's Ariad Pharmaceuticals Inc position peaked at $4.44M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Principal Financial Group's 13F filing for Q1 2017, filed 11 May 2017.